Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

136 results about "Retinal Disorder" patented technology

An abnormal structure or function of the retina and its associated tissues.

Improved raav vectors and methods for transduction of photoreceptors and rpe cells

Disclosed are capsid-modified rAAV particles and expression vectors, as well as compositions and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and using novel capsid-protein-mutated particle or rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for subretinal delivery of therapeutic gene constructs to mammalian photoreceptors and retinal pigment epithelial cells, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and / or in vivo applications including the treatment of a variety of inherited retinal diseases.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Adeno-associated virus variant capsids and methods of use thereof

Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AA V virion comprising the unmodified parental capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.
Owner:4D MOLECULAR THERAPEUTICS INC

Circular preferential hyperacuity perimetry video game to monitor macular and retinal diseases

ActiveUS20150190048A1PhoroptersDiseaseFixation point
Systems and methods for providing a video game to map macular visual acuity comprising a test where a fixation point is ensured by brief simultaneous presentation of central and pericentral targets. The game may be implemented on a hardware platform including a video display, a user input device, and a video camera. The camera is used to monitor ambient light level and the distance between the device and the eyes of the test subject. The game serves as a macular acuity perimeter that produces a map of the acuity of an eye that may be compared with normative data. The type of acuity tested is preferably Vernier acuity, but resolution acuity can also be tested. The test results are transmitted to a health care professional by telecommunications means to facilitate the diagnosis or monitoring of age-related macular degeneration or other relevant eye diseases.
Owner:GOBIQUITY INC

Multi-phasic microphotodetector retinal implant with variable voltage and current capability and apparatus for insertion

A visible and infrared light powered retinal implant is disclosed that is implanted into the subretinal space for electrically inducing formed vision in the eye. The retinal implant includes a stacked microphotodetector arrangement having an image sensing pixel layer and a voltage and current gain adjustment layer for providing variable voltage and current gain to the implant so as to obtain better low light implant performance than the prior art, and to compensate for high retinal stimulation thresholds present in some retinal diseases. A first light filter is positioned on one of the microphotodetectors in each of the image sensing pixels of the implant, and a second light filter is positioned on the other of the microphotodetectors in the image sensing pixel of the implant, each of the microphotodetectors of the pixel to respond to a different wavelength of light to produce a sensation of darkness utilizing the first wavelength, and a sensation of light using the second wavelength, and a third light filter is positioned on a portion of the voltage and current gain adjustment layer that is exposed to light, to allow adjustment of the implant voltage and current gain of the device by use of a third wavelength of light.
Owner:OPTOBIONICS

Treatments for retinal disorders

The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
Owner:CORNELL UNIVERSITY

Very long chain polyunsaturated fatty acids, methods of production, and uses

The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements and food products) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described herein (particularly C28-C38 PUFAs, also referred to herein as supraenes or supraenoics) by the expression, in a production host cell, of the full or partial sequence(s) of Elovl4 DNA / mRNA nucleic acids or ELOVL4 protein sequences encoded thereby, from any species (prokaryotic or eukaryotic) for use in the biosynthesis, production, purification and utilization of VLC-PUFAs in particular by the elongation of C18-C26 saturated fatty acids and PUFAs. The composition of the invention comprises, in various embodiments, a dietary supplement, a food product, a pharmaceutical formulation, a humanized animal milk, an infant formula, a cosmetic item and a biodiesel fuel for example. A pharmaceutical formulation can include, but is not limited to: a drug for treatment of neurodegenerative disease, a retinal disorder, age related maculopathy, a fertility disorder, particularly regarding sperm or testes, or a skin disorder.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA

Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide

Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided.
Owner:SANTEN PHARMA CO LTD

Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

ActiveUS20130216547A1Senses disorderNervous disorderEndothelin converting enzyme 1Retinal Disorder
The present invention provides antibodies that bind big-endothelin-1 (“big-ET-1”), and methods of using same. According to certain embodiments of the invention, the antibodies specifically bind human big-ET-1 but do not bind human small-ET-1 (i.e., the active form of endothelin-1 that results from proteolytic cleavage of big-ET-1 by endothelin-converting enzyme-1 [ECE-1]). According to certain embodiments of the invention, the anti-big-ET-1 antibodies are capable of blocking cleavage of big-ET-1 by ECE-1. The antibodies of the invention are useful for the treatment of big-ET-1-related disorders, including hypertension disorders, fibrotic disorders, neurodegenerative disorders, retinal disorders, pain and cancers.
Owner:REGENERON PHARM INC

Intra-Ocular Implant

An intra ocular implant consisting of optical elements, adapted to forming images on the retina, especially useful in treating presbyopic patients, patients with AMD, patients with other diseases of the retina, and patients in which future development of retinal disorders may occur. An intra ocular implant wherein at least one mirror is operationally connected to the action of the ciliary muscle or its effect on the zonules and capsule of the natural lens; and wherein the mirror is adapted to change curvature, position or optical properties, such that bringing a plurality of objects at different distances into focus is facilitated in presbyopic patients. A lens assembly comprising an intra ocular lens and, an adjustable external or contact lens comprising at least in part of light polarizing material; the assembly at least partially polarizes at least part of the central visual field, at least part of the peripheral visual field or both in any angle.
Owner:LIPSHITZ ISAAC +1

Method and System for Low Coherence Interferometry

Optical Coherence Tomography (OCT) system and apparatus of this instant application is very useful for diagnosis and management of ophthalmic diseases such as retinal diseases and glaucoma etc. Instant innovative OCT diagnostic system leverages advancements in cross technological platforms. The Michelson interferometric system presented in this application could be used for the OCT imaging, which includes biological OCT imaging, medical OCT imaging, ophthalmic OCT imaging, corneal OCT imaging, retinal OCT imaging, and the like. A tunable filter is placed in front of the detector to make the interferometer more sensitive and accurate for examining various samples for diagnosis.
Owner:NETRA SYST

Compositions of very long chain polyunsaturated fatty acids and methods of use

The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements, food products, and pharmaceutic compositions) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described herein (particularly C28-C40 PUFAs, also referred to herein as supraenes or supraenoics) by the expression, in a production host cell, of the full or partial sequence(s) of Elovl4 DNA / mRNA nucleic acids or ELOVL4 protein sequences encoded thereby, from any species (prokaryotic or eukaryotic) for use in the biosynthesis, production, purification and utilization of VLC-PUFAs in particular by the elongation of C18-C26 saturated fatty acids and PUFAs. The composition of the invention comprises, in various embodiments, a dietary supplement, a food product, a nutritional formulation, a pharmaceutical formulation, a humanized animal milk, an infant formula, and a cosmetic item and for example. A pharmaceutical formulation can include, but is not limited to: a composition for enhancing neural development and function, a drug for treatment of neurodegenerative disease, an ocular disorder, a retinal disorder, age related maculopathy, a fertility disorder, particularly regarding sperm or testes, or a skin disorder.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA

Pharmaceuticals containing retinal stem cells

The invention relates to stem cells isolated from the retina of mammals and retinal cells differentiated from these stem cells. The invention also relates to a method of isolating retinal stem cells and inducing retinal stem cells to produce retinal cells. Retinal stem cells may also be induced in vivo to produce retinal cells. The invention also includes pharmaceuticals made with retinal stem cells or retinal cells which may be used to restore vision lost due to diseases, disorders or abnormal physical states of the retina. The invention includes retinal stem cell and retinal cell culture systems for toxicological assays, for isolating genes involved in retinal differentiation or for developing tumour cell lines.
Owner:KOOY DEREK VAN DER +3

Method of treating edematous retinal disorders

The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds, or hydrolysis-resistant mononucleoside triphosphates.
Owner:MERCK SHARP & DOHME LLC

Vision test for determining retinal disease progression

The present invention provides a reading test to measure vision loss. In one embodiment, the vision loss is due to disease progression. The tests are useful in evaluating the effects of intervention in vision deterioration. The tests are non-invasive, simple, quick, sensitive, reproducible, and easy to administer. The tests measure the subject's reading speed and accuracy under defined conditions of illumination and contrast. The results of these tests may be used to determine if treatment of a disease should be initiated, terminated, altered, or remain unchanged.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Lipoxin A4 Protection for Retinal Cells

InactiveUS20100324138A1Inhibit apoptosisBiocideSenses disorderNeuroprotective factorsOxidative Stress Induction
Lipoxin A4 and its analogs have been found to be effective in inhibiting apoptosis of retinal pigment epithelial cells induced by oxidative stress. Thus lipoxin A4 and its analogs, for example, lipoxin A4 epimer 15, can be used to prevent and treat retinal diseases due to the progressive degeneration of photoreceptors and retinal pigment epithelial cells (RPE cells), e.g., the dry form of age-related macula degeneration. They can also be combined with other compounds known to prevent apoptosis in retinal pigment epithelial cells, e.g., docosahexaenoic acid and neuroprotectin D1.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE

Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis

The invention relates to compositions, formulations, vaccines and antibodies for the prevention and / or treatment of aging and brain disorders, including Alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including Alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification. The invention further provides methods for diagnosing or assessing risk of development of brain disorders in humans and animals. The invention further provides animal models for testing novel therapeutics for brain disorders.
Owner:CORTEXYME INC

Use of Inhibitors of Acid Sphingomyelinase to Treat Acquired and Inherited Retinal Degenerations

ActiveUS20150366876A1Efficacy of treatmentLack and slowing of disease progressionBiocideSenses disorderMedicineDisease patient
A method of treating retinal diseases is disclosed that includes the step of administering an effective amount of a composition including an ASMase inhibitor to a retinal disease patient, wherein at least one disease symptom is either lessened or progression of the symptom is delayed.
Owner:WISCONSIN ALUMNI RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products